Boston Scientific Corp
Statements
Segments
US companies must disclose in their mandatory reports how revenue breaks down across business segments, regions and product lines. We read that breakdown for you straight from the annual and quarterly reports (10-K and 10-Q) of Boston Scientific Corp (BSX). It shows which part of the business is growing — and which one is holding it back.
Revenue by business segment
| Segment | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cardiovascular | $7.24B 61.0% | $7.83B 61.5% · +8.1% | $8.82B 61.9% · +12.6% | $10.76B 64.2% · +22.0% | $13.25B 66.0% · +23.2% |
| MedSurg | $4.63B 39.0% | $4.91B 38.5% · +6.0% | $5.42B 38.1% · +10.4% | $5.99B 35.8% · +10.5% | $6.82B 34.0% · +13.9% |
Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.
Revenue by product line
| Segment | 2023 | 2024 | 2025 |
|---|---|---|---|
| Interventional Cardiology & Vascular Therapies | $3.79B 26.6% | $4.20B 25.1% · +10.8% | $4.64B 23.1% · +10.5% |
| Electrophysiology | $800.0M 5.6% | $1.90B 11.4% · +138.0% | $3.33B 16.6% · +74.6% |
| Endoscopy | $2.48B 17.4% | $2.69B 16.0% · +8.3% | $2.92B 14.5% · +8.5% |
| Urology | $1.96B 13.8% | $2.20B 13.1% · +12.0% | $2.71B 13.5% · +23.1% |
| Cardiac Rhythm Management | $2.22B 15.6% | $2.28B 13.6% · +2.8% | $2.33B 11.6% · +2.3% |
| Watchman | $1.27B 8.9% | $1.52B 9.1% · +19.0% | $1.96B 9.8% · +29.2% |
| Neuromodulation | $976.0M 6.9% | $1.11B 6.6% · +13.3% | $1.20B 6.0% · +8.4% |
| Interventional Oncology & Embolization | $736.0M 5.2% | $856.0M 5.1% · +16.3% | $1.00B 5.0% · +16.4% |
Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.
Segment and region names are the ones the company itself uses and are shown as reported. Change and share refer to revenue.
Data as of: August 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Segment figures: SEC EDGAR (10-K/10-Q reports)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.